Research - Paterna, Valencian Community, Spain
ARTHEx pharma is a spin-off company from the University of Valencia focused on the development of Antisense RNA treatments for genetic diseases. The founders of the company are Dr. Beatriz Llamusí and Dr. Ruben Artero. The first product will be the development of a new drug (small molecule) addressed to the treatment of myotonic dystrophy (DM). DM is the most common muscle dystrophy in adults and it is a highly disabling disease with symptoms involving the skeletal musculature, the heart, and the nervous system. Thus, ARTHEx is a company that aims to develop a treatment against this disease based on microRNA inhibitors.The business model proposed is based on an open innovation model in which the biotechnology company develops the products until phase 2 (efficacy), and then licenses them to pharmaceutical multinationals with the capacity to complete the development studies more advanced and its commercialization
Gmail
Google Tag Manager
Mobile Friendly
Amazon AWS
YouTube